Product Overview
Cagrilintide – Research‑Grade Amylin Analogue for Appetite, Metabolic, and Energy‑Balance Pathway Investigation
Synonyms: AM833; Long‑acting amylin analogue
CAS Number: Not publicly assigned (investigational research peptide)
Sequence: Proprietary long‑acting amylin analogue (Novo Nordisk)
Molecular Weight: Not publicly standardised (typically >3 kDa depending on supplier)
Form: Lyophilised powder
Purity: ≥98% (HPLC)
Use: For laboratory research only. Not for human or veterinary use.
Overview
Cagrilintide (AM833) is a long‑acting synthetic analogue of the human peptide amylin, engineered for research into appetite regulation, metabolic signalling, and energy‑balance pathways.
In laboratory settings, it is widely used to investigate amylin‑receptor pharmacology, satiety‑related neurocircuitry, and metabolic homeostasis in controlled non‑human models.
Its extended half‑life and receptor‑selective design make it suitable for in vitro and in vivo studies examining neuroendocrine regulation, food‑intake pathways, and peptide–receptor interactions.
Mechanistic Insights
Preclinical research has explored Cagrilintide in relation to several biological processes:
• Amylin Receptor Activation – Studied for its agonist activity at AMY receptors involved in satiety signalling.
• Appetite‑Regulation Pathways – Investigated for its influence on hypothalamic circuits associated with food intake in non‑human models.
• Metabolic Homeostasis – Examined for its involvement in energy‑balance mechanisms and nutrient‑response pathways.
• Peptide Stability and Duration – Evaluated for its extended activity profile compared with native amylin.
These findings are based on published scientific literature and do not imply any therapeutic or physiological effects in humans.
Research Context
Cagrilintide is utilised exclusively within controlled laboratory environments for:
• Studies involving appetite regulation and satiety pathways
• Investigations into amylin‑receptor pharmacology
• Research on metabolic regulation and energy‑balance models
• Comparative studies with amylin, pramlintide, and multi‑agonist peptides
This material is not intended for therapeutic, diagnostic, or clinical use.
Packaging & Storage
• Supplied as a sterile‑filtered, lyophilised peptide
• Store at –20°C, protected from light and moisture
• Reconstitute under sterile laboratory conditions using bacteriostatic water or a suitable research‑grade diluent
• Store reconstituted solutions at 2–8°C and use according to institutional guidelines
Additional solubility and technical documentation are available to qualified research institutions upon request.
Compliance Notice
This product is intended solely for laboratory research purposes.
It is not approved for human or veterinary administration and must not be incorporated into food, cosmetics, pharmaceuticals, or any product intended for biological exposure.
All information provided is for scientific and educational reference only. Researchers are responsible for ensuring compliance with all applicable regulations, institutional policies, and safety standards.
₄₃₀N₇₈O₈₄
Molecular Weight: ~5,800–6,000 Da (approximate)
Form: Lyophilized powder
Purity: ≥98% (HPLC)
Use: For laboratory research only. Not for human or veterinary use.
? Overview
Cagrilintide is a synthetic peptide analog of human amylin, designed to function as a dual amylin and calcitonin receptor agonist (DACRA). It has been structurally optimized for enhanced receptor binding, metabolic stability, and reduced fibrillogenic potential.
In laboratory settings, Cagrilintide is under investigation for its role in appetite signalling, gastric motility, and hormonal modulation. Its extended half-life supports sustained receptor engagement, making it suitable for long-duration metabolic studies in non-human models.
⚙️ Mechanistic Insights
Preclinical research suggests Cagrilintide may influence multiple pathways:
• Amylin Receptor Activation – Studied for effects on postprandial glucagon modulation, gastric emptying, and satiety signalling
• Calcitonin Receptor Engagement – Explored for its role in appetite regulation and metabolic hormone interaction
• Dual-Receptor Synergy – May support multi-hormonal modulation in energy balance studies
These findings are based on published scientific literature and are not indicative of human outcomes.
? Research Context
Cagrilintide is being evaluated in controlled laboratory environments for its relevance to:
• Appetite signalling and caloric intake modulation
• Glucagon and insulin pathway analysis
• Gastric motility and nutrient absorption models
• Combination studies with GLP-1 analogs in non-human systems
All applications are strictly limited to research use and are not intended for therapeutic, diagnostic, or clinical purposes.
? Packaging & Storage
• Supplied as sterile-filtered lyophilized peptide
• Store at –20°C in a dry, light-protected environment
• Reconstitute under sterile conditions using appropriate laboratory solvents
• Refrigerate reconstituted solution at 2–8°C to preserve bioactivity
Note: Solvent compatibility and formulation protocols are available upon request for qualified research institutions
⚠️ Compliance Notice
This product is intended strictly for laboratory research use. It is not approved for human or veterinary applications and must not be used in food, drugs, or cosmetics. All information is based on published scientific literature and is provided for educational and informational purposes only. Researchers are responsible for ensuring compliance with local laws and institutional guidelines.
